MannKind Corp. (MNKD)
4.09
+0.02
(+0.49%)
USD |
NASDAQ |
Nov 18, 14:16
MannKind EPS Diluted (Quarterly) : -0.0725 for Sept. 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -0.0725 |
| June 30, 2026 | -0.0616 |
| March 31, 2026 | -0.0539 |
| December 31, 2025 | -0.0519 |
| September 30, 2025 | 0.0256 |
| June 30, 2025 | 0.0021 |
| March 31, 2025 | 0.041 |
| December 31, 2024 | 0.0255 |
| September 30, 2024 | 0.0406 |
| June 30, 2024 | -0.0074 |
| March 31, 2024 | 0.0327 |
| December 31, 2023 | 0.0043 |
| September 30, 2023 | 0.0064 |
| June 30, 2023 | -0.0198 |
| March 31, 2023 | -0.0371 |
| December 31, 2022 | -0.0681 |
| September 30, 2022 | -0.0557 |
| June 30, 2022 | -0.1144 |
| March 31, 2022 | -0.1032 |
| December 31, 2021 | -0.1118 |
| September 30, 2021 | -0.0177 |
| June 30, 2021 | -0.1425 |
| March 31, 2021 | -0.0524 |
| December 31, 2020 | -0.1126 |
| September 30, 2020 | -0.049 |
| Date | Value |
|---|---|
| June 30, 2020 | -0.0479 |
| March 31, 2020 | -0.0439 |
| December 31, 2019 | -0.069 |
| September 30, 2019 | -0.0519 |
| June 30, 2019 | -0.0659 |
| March 31, 2019 | -0.0794 |
| December 31, 2018 | -0.0604 |
| September 30, 2018 | -0.1574 |
| June 30, 2018 | -0.16 |
| March 31, 2018 | -0.25 |
| December 31, 2017 | -0.28 |
| September 30, 2017 | -0.31 |
| June 30, 2017 | -0.35 |
| March 31, 2017 | -0.17 |
| December 31, 2016 | 0.56 |
| September 30, 2016 | 1.30 |
| June 30, 2016 | -0.35 |
| March 31, 2016 | -0.30 |
| December 31, 2015 | -3.30 |
| September 30, 2015 | -0.40 |
| June 30, 2015 | -0.35 |
| March 31, 2015 | -0.40 |
| December 31, 2014 | -0.45 |
| September 30, 2014 | -0.45 |
| June 30, 2014 | -0.95 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| United Therapeutics Corp. | 5.709 |
| ACADIA Pharmaceuticals, Inc. | 0.305 |
| Alnylam Pharmaceuticals, Inc. | 15.72 |
| Anika Therapeutics, Inc. | -0.0232 |
| Savara, Inc. | -0.1691 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -23.22M |
| Revenue (Quarterly) | 101.87M |
| Total Expenses (Quarterly) | 125.09M |
| Enterprise Value | 1.648B |
| Gross Profit Margin (Quarterly) | 71.85% |
| Profit Margin (Quarterly) | -22.80% |
| Earnings Yield | -5.87% |
| Normalized Earnings Yield | -5.049 |